Kinase Knowledgebase Continues its 20K Datapoint Quarterly Growth Trajectory

San Diego, CA (February 12, 2007) –Eidogen-Sertanty has announced the next quarterly release of the Kinase Knowledgebase (KKB), continuing its consistent growth of over 20K new data points per quarter. The KKB is Eidogen-Sertanty's database of biological activity data, structure-activity relationships (SAR), and chemical synthesis data focused on protein kinases - one of the most therapeutically important classes of drug targets. The KKB now covers 1,112 journal articles and 1,873 patents with over 253,500 SAR data points. The overall number of unique small molecule structures for kinase modulators in the KKB is now greater than 430,000.  For more information about the Kinase Knowledgebase, please visit the Kinase Knowledgebase Product Description page.

About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations.  Eidogen-Sertanty’s unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization.  To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com.

Contact Information:
Steve Muskal
760-729-0211
pr@eidogen-sertanty.com